The results of the present study may facilitate the development of novel treatment because of a better understanding of the relationship, and the p-IRS-1 in the neurons may also serve as a biomarker of the therapeutic effect of antiglycemic agents in clinical trials [Athauda et al., 2017; Ninds Exploratory Trials in Parkinson Disease (Net-Pd) Fs-Zone Investigators, 2015]. This evidence concerns the gene IRS1 and Parkinson disease.